J. Alam

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis

R. Herndon, R. Rudick, J. Simon, 1998, Neurology.

Pharmacokinetics and Pharmacodynamics of Interferon Beta-la (IFNβ-1a) in Healthy Volunteers after Intravenous, Subcutaneous or Intramuscular Administration

M. Rogge, W. Jones, A. Mcallister, 1997 .

Comparative Pharmacokinetics and Pharmacodynamics of Two Recomhinant Human Interferon Beta-la (IFNβ-la) Products Administered Intramuscularly in Healthy Male and Female Volunteers

S. Goelz, P. Rioux, M. Rogge, 1997, Pharmaceutical Research.

Toxic effects of Talstar, a new synthetic pyrethroid, on blood and liver of rabbit.

A. Shakoori, S. Ali, F. Aziz, 1990 .

Interferon-β treatment of human disease

J. Alam, 1995 .

460 A STUDY OF THE SAFETY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF INX-08189, A NUCLEOTIDE POLYMERASE INHIBITOR, IN HEALTHY SUBJECTS

B. Boehlecke, G. Henson, J. Patti, 2011 .

Formulation d'interferon humain recombinant beta-1a (ifn-beta-1a)

S. Goelz, M. Rogge, J. Alam, 1998 .

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

Gavin J. Cook, M. Gallagher, M. Carrillo, 2023, The Journal of Prevention of Alzheimer's Disease.